Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Tirzepatide
Drug: Insulin Glargine

First Posted Date: 2018-11-05

Last Posted Date: 2022-02-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 2002

Registration Number: NCT03730662

Locations: 🇵🇱
Woj. Zesp. Spec. Opieki Zdrowotnej, Wroclaw, Poland
🇺🇸
Northwestern Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Preferred Primary Care Physicians- Bower Hill, Pittsburgh, Pennsylvania, United States

and more 205 locations

A Study of LY3374849 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3374849 - IV
Drug: Insulin Degludec - SC
Drug: Insulin Degludec - IV
Drug: LY3374849 - SC

First Posted Date: 2018-10-31

Last Posted Date: 2019-10-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 89

Registration Number: NCT03726125

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Dulaglutide Pen
Drug: Semaglutide Pen

First Posted Date: 2018-10-30

Last Posted Date: 2020-04-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 312

Registration Number: NCT03724981

Locations: 🇺🇸
Long Beach Center for Clinical Research, Long Beach, California, United States
🇺🇸
Palm Harbor Medical Associates, Palm Harbor, Florida, United States
🇺🇸
Georgia Clinical Research, Snellville, Georgia, United States

and more 11 locations

A Study of Mirikizumab in Participants With Plaque Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: Drug Cocktail
Drug: Mirikizumab

First Posted Date: 2018-10-25

Last Posted Date: 2024-01-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 29

Registration Number: NCT03718884

Locations: 🇺🇸
High Point Clinical Trials Center, High Point, North Carolina, United States
🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Avail Clinical Research LLC, DeLand, Florida, United States

A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

Phase 1

Completed

Conditions: Alzheimer Disease

Interventions: Drug: LY3372993
Drug: Placebo

First Posted Date: 2018-10-25

Last Posted Date: 2019-06-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 36

Registration Number: NCT03720548

Locations: 🇺🇸
Avail Clinical Research LLC, DeLand, Florida, United States
🇺🇸
Progressive Medical Research, Port Orange, Florida, United States
🇺🇸
Collaborative Neuroscience Network - CNS, Long Beach, California, United States

and more 7 locations

A Safety Study of LY3462817 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: LY3462817 IV
Drug: Placebo
Biological: LY3462817 SC

First Posted Date: 2018-10-23

Last Posted Date: 2019-12-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 64

Registration Number: NCT03715192

Locations: 🇸🇬
Lilly Nus Centre for Clin Pharmacology, Singapore, Singapore

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Abemaciclib
Drug: Abiraterone Acetate
Drug: Prednisone
Drug: Placebo

First Posted Date: 2018-10-16

Last Posted Date: 2024-10-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 350

Registration Number: NCT03706365

Locations: 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
🇺🇸
The University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States

and more 107 locations

A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Abemaciclib

First Posted Date: 2018-10-12

Last Posted Date: 2024-04-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 72

Registration Number: NCT03703466

Locations: 🇹🇷
Akdeniz University Medical Faculty, Antalya, Turkey
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇹🇷
Medical Park Izmir Hospital, Izmir, Turkey

and more 12 locations

A Study of LY3361237 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3361237 - SC
Drug: Placebo - SC
Drug: LY3361237 - IV
Drug: Placebo - IV

First Posted Date: 2018-10-04

Last Posted Date: 2019-09-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 64

Registration Number: NCT03695198

Locations: 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States

A Study of LY3451838 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3451838
Drug: Placebo

First Posted Date: 2018-10-02

Last Posted Date: 2020-03-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 53

Registration Number: NCT03692949

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy